	US 12,258,557 B2
	Humanized cell line
Yoshihiro Kawaoka, Middleton, WI (US); Kosuke Takada, Tokyo (JP); and Masaki Imai, Kawasaki (JP)
Assigned to Wisconsin Alumni Research Foundation (WARF), Madison, WI (US); and The University of Tokyo, Tokyo (JP)
Filed by The University of Tokyo, Tokyo (JP); and Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
Filed on Nov. 30, 2023, as Appl. No. 18/525,460.
Application 18/525,460 is a continuation of application No. 16/785,449, filed on Feb. 7, 2020, granted, now 11,851,648.
Claims priority of provisional application 62/803,266, filed on Feb. 8, 2019.
Prior Publication US 2024/0318167 A1, Sep. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/10 (2006.01); C12N 5/071 (2010.01); C12N 7/02 (2006.01); C12N 9/10 (2006.01); C12Q 1/04 (2006.01)

CPC C12N 15/102 (2013.01) [C12N 5/0602 (2013.01); C12N 9/10 (2013.01); C12Q 1/04 (2013.01); C12Y 204/99001 (2013.01)]

19 Claims

1. An isolated recombinant mammalian cell, comprising a reduced amount of cell surface β-galactoside α2,3 sialyl residues relative to a corresponding non-recombinant mammalian cell, wherein β-galactoside α2,3 sialyltransferase (ST3Gal) genes are mutated so as to reduce the amount of the cell surface β-galactoside α2,3 sialyl residues, wherein the ST3Gal genes include ST3Gal-I, ST3Gal-II, ST3Gal-III, ST3Gal-IV, ST3Gal-V, ST3Gal-VI, and ST3Gal-II-like genes, and wherein the recombinant mammalian cell comprises an expression cassette encoding human β-galactoside α2,6 sialyltransferase (ST6Gal), wherein the reduced amount of cell surface 3-galactoside a2,3 sialyl residues is the result of mutation of the ST3Gal genes in the recombinant cell.